Abstract
Parkinsons disease (PD) is a complex neurodegenerative disorder characterised by dopaminergic cell loss in the substantia nigra. In addition, neurodegeneration occurs at a number of extra-nigral locations and involves a variety of non-dopaminergic neurotransmitter systems. Etiopathogenic mechanisms leading to cell death include oxidative stress and free radical generation, mitochondrial dysfunction, glutamate receptor mediated excitotoxicity, inflammation, oligodendrocytic interaction and neurotrophic factors, ubiquitin-proteosome system involvement, autophagy and apoptosis. Each of these is a potential target for novel pharmacotherapies including bioenergetic agents, inhibitors of excitotoxicity, neurotrophic factors, proteosomal enhancers and anti-apoptotic agents. Evidence has also been gained from cell culture and animal models for the potential disease modifying action of currently available dopaminergic therapies. These drugs have undergone clinical evaluation using studies with novel designs including “delayed start” methodology and studies using neuroimaging as a surrogate marker of dopaminergic cell loss. It is estimated from clinical, pathological and imaging studies that at least 50% of dopaminergic neurons are lost before the development of significant motor symptoms with a pre-motor phase of approximately 6-8 years. A number of pre- and post-synaptic neuroplastic homeostatic mechanisms occur during this period to maintain motor function. However these changes have been implicated in the development of motor complications (wearing “off” and dyskinesias). The evidence for treatments of motor complications in PD is discussed as are potential non-dopaminergic therapeutic targets to delay or improve motor complications.
Keywords: Parkinson's disease, Alpha-synuclein, PINK1, LRRK2, mitochondria, oxidative stress, Lewy body
Current Topics in Medicinal Chemistry
Title: Etiopathogenesis and Treatment of Parkinsons Disease
Volume: 9 Issue: 10
Author(s): David A. Gallagher and Anthony H. V. Schapira
Affiliation:
Keywords: Parkinson's disease, Alpha-synuclein, PINK1, LRRK2, mitochondria, oxidative stress, Lewy body
Abstract: Parkinsons disease (PD) is a complex neurodegenerative disorder characterised by dopaminergic cell loss in the substantia nigra. In addition, neurodegeneration occurs at a number of extra-nigral locations and involves a variety of non-dopaminergic neurotransmitter systems. Etiopathogenic mechanisms leading to cell death include oxidative stress and free radical generation, mitochondrial dysfunction, glutamate receptor mediated excitotoxicity, inflammation, oligodendrocytic interaction and neurotrophic factors, ubiquitin-proteosome system involvement, autophagy and apoptosis. Each of these is a potential target for novel pharmacotherapies including bioenergetic agents, inhibitors of excitotoxicity, neurotrophic factors, proteosomal enhancers and anti-apoptotic agents. Evidence has also been gained from cell culture and animal models for the potential disease modifying action of currently available dopaminergic therapies. These drugs have undergone clinical evaluation using studies with novel designs including “delayed start” methodology and studies using neuroimaging as a surrogate marker of dopaminergic cell loss. It is estimated from clinical, pathological and imaging studies that at least 50% of dopaminergic neurons are lost before the development of significant motor symptoms with a pre-motor phase of approximately 6-8 years. A number of pre- and post-synaptic neuroplastic homeostatic mechanisms occur during this period to maintain motor function. However these changes have been implicated in the development of motor complications (wearing “off” and dyskinesias). The evidence for treatments of motor complications in PD is discussed as are potential non-dopaminergic therapeutic targets to delay or improve motor complications.
Export Options
About this article
Cite this article as:
Gallagher A. David and Schapira H. V. Anthony, Etiopathogenesis and Treatment of Parkinsons Disease, Current Topics in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/156802609789378227
DOI https://dx.doi.org/10.2174/156802609789378227 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Strategies for the Development of Novel Antipsychotic Drugs
Mini-Reviews in Medicinal Chemistry Disorders of Consciousness and Pharmaceuticals that Act on Oxygen Based Amino Acid and Monoamine Neurotransmitter Pathways of the Brain
Current Pharmaceutical Design Polyamine Modulation of NMDARs as a Mechanism to Reduce Effects of Alcohol Dependence
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacological Profile of Antipsychotics at Monoamine Receptors: Atypicality Beyond 5-HT2A Receptor Blockade
CNS & Neurological Disorders - Drug Targets TRPV1 Channel: A Potential Drug Target for Treating Epilepsy
Current Neuropharmacology Freezing of Gait in Parkinsonism and its Potential Drug Treatment
Current Neuropharmacology Personalized Medicine: Pharmacogenetics in Psychiatry
Current Pharmacogenomics and Personalized Medicine Regression to the Mean: Implications for Clinical Trials of Psychotropic Agents in Dementia
Current Alzheimer Research Effect of Polyherbal Drug Majun Falasfa on the Transgenic Drosophila Model of Parkinson’s Disease
Current Traditional Medicine The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis
Current Drug Targets Current Concepts in Gastric Motility in Diabetes Mellitus
Current Diabetes Reviews Antidepressants: Update on Benefits and Risks
Current Psychopharmacology Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease
Current Aging Science Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Poor Prognostic Outcome in Cerebral Venous Sinus Thrombosis Associated with Dyskinesia and Elevated Platelet Volume
Current Neurovascular Research Membrane Pathology in Schizophrenia: Implication for Arachidonic Acid Signaling
Current Medicinal Chemistry - Central Nervous System Agents Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology